Back to top
more

ABIOMED, Inc. (ABMD)

(Delayed Data from NSDQ)

$307.60 USD

307.60
292,592

-17.71 (-5.44%)

Updated Mar 3, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (181 out of 254)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Headquartered in Danvers, MA and founded in 1981, ABIOMED Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. Abiomed’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.

Impella 2.5 is primarily used by interventional cardiologists to support patients in the cardiac catheterization lab (cath lab) for partial circulatory support for up to six hours.

The Impella 5.0 and Impella LD received 510(K) clearances for circulatory support for up to six ...

General Information

ABIOMED, Inc.

22 CHERRY HILL DR

DANVERS, MA 01923

Phone: 978-646-1400

Fax: 978-777-8411

Web: http://www.abiomed.com

Email: ir@abiomed.com

Industry Medical - Instruments
Sector Medical
Fiscal Year End March
Last Reported Quarter 12/31/2020
Next EPS Date 4/29/2021

EPS Information

Current Quarter EPS Consensus Estimate 1.11
Current Year EPS Consensus Estimate 4.81
Estimated Long-Term EPS Growth Rate 20.50
Next EPS Report Date 4/29/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 325.31
52 Week High 387.40
52 Week Low 119.01
Beta 1.37
20 Day Moving Average 314,605.34
Target Price Consensus 328.00

ABMD

% Price Change
4 Week -6.48
12 Week 18.88
YTD 0.34
% Price Change Relative to S&P 500
4 Week -7.54
12 Week 13.72
YTD -2.62
Share Information
Shares Outstanding (millions) 45.23
Market Capitalization (millions) 14,714.09
Short Ratio NA
Last Split Date 10/2/2000
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 67.68
Trailing 12 Months 86.52
PEG Ratio 3.30
EPS Growth
vs. Previous Year 5.41%
vs. Previous Quarter 15.84%
   
Sales Growth
vs. Previous Year 4.55%
vs. Previous Quarter 10.44%
   
Price Ratios
Price/Book 11.66
Price/Cash Flow 61.69
Price / Sales 18.10
ROE
12/31/20 14.86
9/30/20 15.34
6/30/20 16.17
ROA
12/31/20 13.12
9/30/20 13.51
6/30/20 14.21
Current Ratio
12/31/20 5.76
9/30/20 6.81
6/30/20 5.61
Quick Ratio
12/31/20 5.08
9/30/20 6.02
6/30/20 4.81
Operating Margin
12/31/20 21.07
9/30/20 21.00
6/30/20 21.31
Net Margin
12/31/20 24.66
9/30/20 25.89
6/30/20 19.88
Pre-Tax Margin
12/31/20 31.25
9/30/20 33.67
6/30/20 26.91
Book Value
12/31/20 27.89
9/30/20 26.17
6/30/20 24.46
Inventory Turnover
12/31/20 1.80
9/30/20 1.74
6/30/20 1.67
Debt-to-Equity
12/31/20 0.00
9/30/20 0.00
6/30/20 0.00
Debt to Capital
12/31/20 0.00
9/30/20 0.00
6/30/20 0.00